#PharmaHistory #Statins #RegulatoryScience #DrugApproval #PatientSafety To view or add a comment, sign in Novo Nordisk has received a warning letter from the FDA regarding significant violations related to the reporting of serious adverse events associated with its weight-loss and diabetes medications, including Ozempic, Wegovy (semaglutide), and Saxenda (liraglutide)
doi: 10.3390/microorganisms13051139
The uptake rate of Rho123 was markedly lower in the mitochondria pre-treated with colistin than that in the untreated mitochondria (slope 0.29 vs 0.57, P = 0.0005), indicating that colistin induced the depolarization of the mitochondrial inner membrane
Yes, with the right protocol adjustments
Diabetic retinopathy rapid improvement in blood glucose control, particularly with semaglutide, may temporarily worsen diabetic retinopathy in patients with pre-existing eye disease